Pompsch Mosche, Fisenkci Neslinur, Horn Peter A, Kraemer Markus, Lindemann Monika
Department of Neurology, Alfried Krupp Hospital, Alfried-Krupp-Straße 21, 45130, Essen, Germany.
Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Neurol Res Pract. 2021 Nov 22;3(1):60. doi: 10.1186/s42466-021-00158-5.
Patients with multiple sclerosis receiving ocrelizumab-treatment are in desperate need of a protection against SARS-CoV-2 infection.
In this study, Euroimmun semi-quantitative Anti-SARS-CoV-2 IgG for detection of humoral response and ELISpot assays for detection of SARS-CoV-2-specific T-cell-response were used in 10 ocrelizumab-treated patients with multiple sclerosis twice vaccinated with Comirnaty® mRNA vaccine. This data was compared with a control group of 20 age- and sex-matched healthy volunteers, who had all previously received a full SARS-CoV-2 mRNA vaccination with Comirnaty® or Spikevax®.
While all subjects in the control group had high humoral response to the vaccination, in B-cell-depleted individuals a significantly reduced antibody response to vaccination against SARS-CoV-2 was observed. SARS-CoV-2 specific T-cell-response, however, did not differ significantly between both cohorts.
T-cell-mediated response to Comirnaty® vaccination is observable despite attenuated humoral response in B-cell-depleted patients. This might enable partial protection against COVID-19. Trial registration Retrospectively registered.
接受奥瑞珠单抗治疗的多发性硬化症患者迫切需要预防严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染。
在本研究中，对10名接受奥瑞珠单抗治疗且已两次接种Comirnaty® mRNA疫苗的多发性硬化症患者，使用欧蒙半定量抗SARS-CoV-2 IgG检测体液反应，并采用酶联免疫斑点试验（ELISpot）检测SARS-CoV-2特异性T细胞反应。将该数据与20名年龄和性别匹配的健康志愿者对照组进行比较，这些志愿者之前均已完成Comirnaty®或Spikevax®的SARS-CoV-2 mRNA全程接种。
虽然对照组的所有受试者对疫苗接种都有高体液反应，但在B细胞耗竭的个体中，观察到针对SARS-CoV-2疫苗接种的抗体反应显著降低。然而，两个队列之间的SARS-CoV-2特异性T细胞反应没有显著差异。
尽管B细胞耗竭患者的体液反应减弱，但仍可观察到对Comirnaty®疫苗接种的T细胞介导反应。这可能实现对冠状病毒病（COVID-19）的部分保护。试验注册 回顾性注册。
